New Radionuclide Therapy Identified for HER2-Positive Breast Cancer Patients

A promising radionuclide treatment may offer new therapeutic options for breast cancer patients, according to research published in The Journal of Nuclear Medicine. The treatment combines radioactive iodine therapy with single-domain antibodies that target the human epidermal growth factor receptor type 2 (HER2) antigen to destroy cancer cells. This first-in-human study demonstrates the safety and efficacy of the radionuclide in patients with HER2-positive breast cancer.

JNM Press release

JNM Publication

Your browser is not supported. Update your browser for more security, speed and to make the most of this site.